The Argentine government has taken a significant step by deregulating pharmaceutical patents, a move announced by the Minister of Deregulation and State Transformation, Federico Sturzenegger. This change, documented in Resolution Joint 1/2026, effectively removes existing restrictions for registering pharmaceuticals, which had been stipulated by the previous regulation established in 2012. Sturzenegger highlighted this decision on social media, emphasizing Argentina's reintegration into the international pharmaceutical market with the phrase 'Argentina returns to the world'.

The rescinded regulation had previously imposed stringent guidelines on the operations of the National Institute of Industrial Property (INPI), limiting its ability to evaluate and grant patents. By abolishing these limits, the government aims to facilitate easier access for pharmaceutical companies to register their products, promoting a more competitive environment. The decision is seen as a critical move towards modernizing Argentina's pharmaceutical sector, potentially increasing foreign investment and improving access to medications for the population.

Critics, however, might express concerns over the implications of such deregulation, fearing that removing patent barriers could impact pharmaceutical innovation and accessibility of essential drugs. As the government aligns domestic regulations with global standards, the long-term effects on the quality of healthcare and local pharmaceutical development will likely be subjects of ongoing debate within the country.